Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEED: Patient-Specific Biologically Targeted Therapy for Pediatric Refractory/Recurrent Brain Tumors
NCT02015728Unknown
- Sponsor
- Seattle Children's
- Start
- Dec 2013
- Primary completion
- Nov 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of sorafenib, everolimus, erlotinib and dasatinib in brain tumor (4 arms), sponsored by Seattle Children's. Primary endpoint: Feasibility at 3 years. Status: unknown.
02
Drugs
sorafenibeverolimuserlotinibdasatinib
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT02015728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015728.